Q2 2023 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2023-08-11 · accession 0001104659-23-090491
$625.4M
Reported value
30
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $73.3M | 11.7% | 3,082,622 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $55.5M | 8.87% | 4,684,132 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $54.2M | 8.67% | 3,000,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $45.5M | 7.28% | 2,230,127 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $45.5M | 7.27% | 1,726,214 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $41.7M | 6.67% | 3,517,125 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $40.9M | 6.54% | 2,484,960 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $26.3M | 4.20% | 2,916,667 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $26.0M | 4.16% | 2,972,869 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $25.5M | 4.07% | 1,973,251 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $24.5M | 3.91% | 2,173,913 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $23.1M | 3.70% | 2,105,386 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $20.3M | 3.25% | 6,351,531 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $20.1M | 3.21% | 1,326,200 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $18.0M | 2.87% | 1,090,000 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $16.6M | 2.66% | 2,142,856 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $10.8M | 1.73% | 1,040,754 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $8.2M | 1.31% | 3,422,397 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $7.2M | 1.16% | 5,658,034 | Common | SOLE |
| 88369M101 | — | THESEUS PHARMACEUTICALS INC | $7.2M | 1.15% | 770,000 | Common | SOLE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $6.3M | 1.01% | 2,208,812 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $6.2M | 0.99% | 3,886,246 | Common | SOLE |
| 74006W108 | — | PRAXIS PRECISION MEDICINES I | $6.1M | 0.98% | 5,304,410 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $5.2M | 0.84% | 288,949 | Common | SOLE |
| 55234L105 | LYRAGBP | LYRA THERAPEUTICS INC | $3.8M | 0.61% | 924,170 | Common | SOLE |
| 00773J103 | — | AEGLEA BIOTHERAPEUTICS INC | $2.9M | 0.46% | 6,343,221 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $1.8M | 0.29% | 353,629 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $1.5M | 0.24% | 268,532 | Common | SOLE |
| N01045108 | — | AFFIMED N V | $854,571 | 0.14% | 1,428,571 | Common | SOLE |
| 05338F207 | — | AVALO THERAPEUTICS INC | $444,000 | 0.07% | 1,250,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.